$25.76
0.38% yesterday
Nasdaq, Nov 25, 09:18 pm CET
ISIN
US04335A1051
Symbol
ARVN
Sector
Industry

Arvinas, Inc. Stock price

$25.15
-0.77 2.97% 1M
-10.08 28.61% 6M
-16.01 38.90% YTD
+1.04 4.31% 1Y
-53.10 67.86% 3Y
-9.36 27.12% 5Y
+9.10 56.70% 10Y
Nasdaq, Closing price Mon, Nov 25 2024
-0.71 2.75%
ISIN
US04335A1051
Symbol
ARVN
Sector
Industry

Key metrics

Market capitalization $1.73b
Enterprise Value $608.03m
P/E (TTM) P/E ratio negative
EV/Sales (TTM) EV/Sales 3.77
P/S ratio (TTM) P/S ratio 10.73
P/B ratio (TTM) P/B ratio 2.95
Revenue growth (TTM) Revenue growth 0.94%
Revenue (TTM) Revenue $161.10m
EBIT (operating result TTM) EBIT $-357.40m
Cash position $1.12b
EPS (TTM) EPS $-4.67
P/E forward negative
P/S forward 6.64
EV/Sales forward 2.34
Short interest 13.05%
Show more

Is Arvinas, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

Arvinas, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

20 Analysts have issued a Arvinas, Inc. forecast:

18x Buy
90%
2x Hold
10%

Analyst Opinions

20 Analysts have issued a Arvinas, Inc. forecast:

Buy
90%
Hold
10%

Financial data from Arvinas, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
161 161
1% 1%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 153 153
107% 107%
95%
- Research and Development Expense 360 360
6% 6%
224%
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -357 -357
15% 15%
-222%
Net Profit -309 -309
4% 4%
-192%

In millions USD.

Don't miss a Thing! We will send you all news about Arvinas, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Arvinas, Inc. Stock News

Neutral
GlobeNewsWire
about 14 hours ago
NEW HAVEN, Conn., Nov. 25, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) today announced that three posters for vepdegestrant, including clinical data, will be presented at the 2024 San Antonio Breast Cancer Symposium (SABCS), being held December 10-13, 2024, in San Antonio, Texas. Vepdegestrant is a novel investigational PROTAC estrogen receptor (ER) degrader that is being jointly deve...
Neutral
GlobeNewsWire
22 days ago
NEW HAVEN, Conn., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will participate in two upcoming investor conferences:
Neutral
Seeking Alpha
27 days ago
Arvinas, Inc. (NASDAQ:ARVN ) Q3 2024 Earnings Conference Call October 30, 2024 8:00 AM ET Company Participants Jeff Ball - Chief Financial Officer John Houston - Chief Executive Officer, President and Chairperson Noah Berkowitz - Chief Medical Officer Andrew Sake - Chief Financial Officer Angela Cacace - Chief Scientific Officer Conference Call Participants Akash Tewari - Jefferies Brad Canino ...
More Arvinas, Inc. News

Company Profile

Arvinas, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of therapies to degrade disease-causing proteins. Its lead products include ARV-110 and ARV-471. The company was founded in February 2013 and is headquartered in New Haven, CT.

Head office United States
CEO John Houston
Employees 445
Founded 2013
Website www.arvinas.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today